Plain-English translation of NCT05182840 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Kidney disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial examined whether a new medication called could help protect kidney function in people with chronic kidney disease. Researchers tested the medication at different doses, both by itself and combined with another kidney-protective drug called , to see which approach worked best. Some participants received the actual medications while others received placebo (inactive pills) to compare results fairly.
Chronic kidney disease is a serious condition that can get worse over time, and people need better treatment options to slow or stop kidney damage. This trial investigated whether this new treatment could offer additional protection beyond what existing medications provide.
Participants attended about 12 visits over 6 months (with some visits possible by phone or video from home). The trial had two phases: first, everyone took either the medication or placebo daily for 2 months; then, they were divided into groups receiving different doses of the new medication or placebo combined with the first medication for 3.5 months. Throughout the trial, participants collected urine samples at home for kidney function testing and had regular health check-ups to monitor for any side effects.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States